On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 convalescent plasma. The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment. Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.
We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines.
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
We are very excited to launch our new website! Please take a few moments to click around and explore...
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...